The IsoTect–Prostate test is an in vitro diagnostic test developed by Capillon Analytics, licensed and owned by Kreftect Inc. It is a groundbreaking, non-invasive test to detect prostate cancer early while it’s still localized and treatable.
Our technology is based on a non-invasive test to detect prostate cancer while it’s still localized and treatable. IsoTect uses a small sample of hair, which acts as a natural archive of chemical changes in the body. We use Mass Spectrometry to analyze the composition of stable isotopes in elements like copper, sulfur, and zinc that are found in much higher concentrations in hair than in blood. This analysis allows us to identify subtle chemical changes linked to the metabolism of cancer. Our specially designed computer program carefully reviews and analyzes these changes to help detect the presence of cancer in the body. This method allows us to detect cancer-related signals with high sensitivity and specificity. Our test, IsoTect is designed to complement existing screening methods like PSA tests.
Capillon Analytics part of Kreftect Inc
Scheelevägen 8, 223 63 Lund, Sverige